Epigenetic Markers of B-Cell Function in Low Birth Weight Infants
NCT ID: NCT00925925
Last Updated: 2015-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
64 participants
OBSERVATIONAL
2009-06-30
2012-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study will determine the ratio of B1b to B1a lymphocyte subpopulations in the cord blood of infants born LBW in the late preterm to term gestations (\> 34 weeks at birth) and compare those ratios with those of normal birth weight (NBW) controls in a nested case control study design.
Furthermore, animal studies suggest that the expression patterns of CD5 and CD19 proteins determines the cellular phenotype of the B lymphocyte, that of a B1a or a B1b cell, and that the regulatory regions controlling their expression are epigenetically vulnerable. The investigators will therefore isolate DNA and RNA from both B lymphocyte subpopulations and determine whether epigenetic changes to the regulatory regions of the genes coding for CD5 and CD19 protein expression occur in LBW lymphocyte subpopulations as compared to the lymphocytes from NBW infants.
This proposal will be the first human study to examine epigenetic determination of a maladaptive phenotype following LBW status at birth in a specific cell type leading to a specific impairment of innate and adaptive immunity.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Future of Beta Cells in Adults With Genetic Abnormality Behind Neonatal Diabetes
NCT02072551
Leukemia Inhibitory Factor Level in Intrauterine Growth Restriction Neonates
NCT02518126
Regulation Of Maternal Fuel Supply And Neonatal Adiposity
NCT00826904
Mother Infant Nutrition Study
NCT04132310
The Biomarker Study
NCT01148654
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Normal Birth Weight (NBW)
Term, healthy infants born at normal birth weights
Cord blood collection for analysis
Cord blood will be collected from the placentas at delivery for analysis
Low Birth Weight (LBW)
Infants born at \> or equal to 34 0/7 weeks with a birth weight at \< or equal to 10% for gestational age at birth (Small for Gestational Age, SGA)
Cord blood collection for analysis
Cord blood will be collected from the placentas at delivery for analysis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cord blood collection for analysis
Cord blood will be collected from the placentas at delivery for analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For LBW group:
* Gestational age \> or = to 34 0/7 weeks
* Birth weight \< or = to 10% for gestational age
* For NBW group:
* Term infant controls delivered without complication
* Adequate cord blood sample obtained directly after birth
* Parents or guardians must have signed informed consent
Exclusion Criteria
2 Hours
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Department of Health and Human Services
FED
University of Utah
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Utah
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christian C Yost, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Utah
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Utah
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35580
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.